Canagliflozin Facilitates Reverse Cholesterol Transport Through Activation of AMPK/ABC Transporter Pathway
Yingnan Zhao,1,2 Yanping Li,2 Qinhui Liu,1 Qin Tang,1,2 Zijing Zhang,1,2 Jinhang Zhang,1,2 Cuiyuan Huang,1,2 Hui Huang,1,2 Guorong Zhang,1,2 Jian Zhou,1,2 Jiamin Yan,1,2 Yan Xia,1,2 Zhiyong Zhang,1,2 Jinhan He1,2 1Department of Pharmacy, National Clinical Research Center for Geriatrics, West China H...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-05-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/canagliflozin-facilitates-reverse-cholesterol-transport-through-activa-peer-reviewed-fulltext-article-DDDT |
| _version_ | 1823932883383877632 |
|---|---|
| author | Zhao Y Li Y Liu Q Tang Q Zhang Z Zhang J Huang C Huang H Zhang G Zhou J Yan J Xia Y Zhang Z He J |
| author_facet | Zhao Y Li Y Liu Q Tang Q Zhang Z Zhang J Huang C Huang H Zhang G Zhou J Yan J Xia Y Zhang Z He J |
| author_sort | Zhao Y |
| collection | DOAJ |
| description | Yingnan Zhao,1,2 Yanping Li,2 Qinhui Liu,1 Qin Tang,1,2 Zijing Zhang,1,2 Jinhang Zhang,1,2 Cuiyuan Huang,1,2 Hui Huang,1,2 Guorong Zhang,1,2 Jian Zhou,1,2 Jiamin Yan,1,2 Yan Xia,1,2 Zhiyong Zhang,1,2 Jinhan He1,2 1Department of Pharmacy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People’s Republic of China; 2Laboratory of Clinical Pharmacy and Adverse Drug Reaction, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People’s Republic of ChinaCorrespondence: Zhiyong Zhang; Jinhan HeDepartment of Pharmacy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People’s Republic of ChinaTel/Fax +86-28-85426416Email asg-yong@163.com; jinhanhe@scu.edu.cnBackground and Purpose: Cholesterol is an essential lipid and its homeostasis is a major factor for many diseases, such as hyperlipidemia, atherosclerosis, diabetes, and obesity. Sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin (Cana) is a new kind of hypoglycemic agent, which decreases urinary glucose reabsorption and reduces hyperglycemia. Cana has been shown to regulate serum lipid, decrease serum triglyceride and increase serum high-density lipoprotein-cholesterol (HDL-C), and improve cardiovascular outcomes. But evidence of how Cana impacted the cholesterol metabolism remains elusive.Methods: We treated Cana on mice with chow diet or western diet and then detected cholesterol metabolism in the liver and intestine. To explore the mechanism, we also treated hepG2 cells and Caco2 cells with different concentrations of Cana.Results: In this study, we showed that Cana facilitated hepatic and intestinal cholesterol efflux. Mechanically, Cana via activating adenosine monophosphate-activated protein kinase (AMPK) increased the expression of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8 in liver and intestine, increased biliary and fecal cholesterol excretion.Conclusion: This research confirms that Cana regulates cholesterol efflux and improves blood and hepatic lipid; this may be a partial reason for improving cardiovascular disease.Keywords: canagliflozin, ATP-binding cassette (ABC) transporters G5/8, cholesterol efflux, AMPK |
| first_indexed | 2024-12-16T21:58:21Z |
| format | Article |
| id | doaj.art-93cf4136e27f4296ab447b928861997b |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-12-16T21:58:21Z |
| publishDate | 2021-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-93cf4136e27f4296ab447b928861997b2022-12-21T22:14:41ZengDove Medical PressDrug Design, Development and Therapy1177-88812021-05-01Volume 152117212864877Canagliflozin Facilitates Reverse Cholesterol Transport Through Activation of AMPK/ABC Transporter PathwayZhao YLi YLiu QTang QZhang ZZhang JHuang CHuang HZhang GZhou JYan JXia YZhang ZHe JYingnan Zhao,1,2 Yanping Li,2 Qinhui Liu,1 Qin Tang,1,2 Zijing Zhang,1,2 Jinhang Zhang,1,2 Cuiyuan Huang,1,2 Hui Huang,1,2 Guorong Zhang,1,2 Jian Zhou,1,2 Jiamin Yan,1,2 Yan Xia,1,2 Zhiyong Zhang,1,2 Jinhan He1,2 1Department of Pharmacy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People’s Republic of China; 2Laboratory of Clinical Pharmacy and Adverse Drug Reaction, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People’s Republic of ChinaCorrespondence: Zhiyong Zhang; Jinhan HeDepartment of Pharmacy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People’s Republic of ChinaTel/Fax +86-28-85426416Email asg-yong@163.com; jinhanhe@scu.edu.cnBackground and Purpose: Cholesterol is an essential lipid and its homeostasis is a major factor for many diseases, such as hyperlipidemia, atherosclerosis, diabetes, and obesity. Sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin (Cana) is a new kind of hypoglycemic agent, which decreases urinary glucose reabsorption and reduces hyperglycemia. Cana has been shown to regulate serum lipid, decrease serum triglyceride and increase serum high-density lipoprotein-cholesterol (HDL-C), and improve cardiovascular outcomes. But evidence of how Cana impacted the cholesterol metabolism remains elusive.Methods: We treated Cana on mice with chow diet or western diet and then detected cholesterol metabolism in the liver and intestine. To explore the mechanism, we also treated hepG2 cells and Caco2 cells with different concentrations of Cana.Results: In this study, we showed that Cana facilitated hepatic and intestinal cholesterol efflux. Mechanically, Cana via activating adenosine monophosphate-activated protein kinase (AMPK) increased the expression of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8 in liver and intestine, increased biliary and fecal cholesterol excretion.Conclusion: This research confirms that Cana regulates cholesterol efflux and improves blood and hepatic lipid; this may be a partial reason for improving cardiovascular disease.Keywords: canagliflozin, ATP-binding cassette (ABC) transporters G5/8, cholesterol efflux, AMPKhttps://www.dovepress.com/canagliflozin-facilitates-reverse-cholesterol-transport-through-activa-peer-reviewed-fulltext-article-DDDTcanagliflozinatp-binding cassette (abc) transporters g5/8cholesterol effluxampk |
| spellingShingle | Zhao Y Li Y Liu Q Tang Q Zhang Z Zhang J Huang C Huang H Zhang G Zhou J Yan J Xia Y Zhang Z He J Canagliflozin Facilitates Reverse Cholesterol Transport Through Activation of AMPK/ABC Transporter Pathway Drug Design, Development and Therapy canagliflozin atp-binding cassette (abc) transporters g5/8 cholesterol efflux ampk |
| title | Canagliflozin Facilitates Reverse Cholesterol Transport Through Activation of AMPK/ABC Transporter Pathway |
| title_full | Canagliflozin Facilitates Reverse Cholesterol Transport Through Activation of AMPK/ABC Transporter Pathway |
| title_fullStr | Canagliflozin Facilitates Reverse Cholesterol Transport Through Activation of AMPK/ABC Transporter Pathway |
| title_full_unstemmed | Canagliflozin Facilitates Reverse Cholesterol Transport Through Activation of AMPK/ABC Transporter Pathway |
| title_short | Canagliflozin Facilitates Reverse Cholesterol Transport Through Activation of AMPK/ABC Transporter Pathway |
| title_sort | canagliflozin facilitates reverse cholesterol transport through activation of ampk abc transporter pathway |
| topic | canagliflozin atp-binding cassette (abc) transporters g5/8 cholesterol efflux ampk |
| url | https://www.dovepress.com/canagliflozin-facilitates-reverse-cholesterol-transport-through-activa-peer-reviewed-fulltext-article-DDDT |
| work_keys_str_mv | AT zhaoy canagliflozinfacilitatesreversecholesteroltransportthroughactivationofampkabctransporterpathway AT liy canagliflozinfacilitatesreversecholesteroltransportthroughactivationofampkabctransporterpathway AT liuq canagliflozinfacilitatesreversecholesteroltransportthroughactivationofampkabctransporterpathway AT tangq canagliflozinfacilitatesreversecholesteroltransportthroughactivationofampkabctransporterpathway AT zhangz canagliflozinfacilitatesreversecholesteroltransportthroughactivationofampkabctransporterpathway AT zhangj canagliflozinfacilitatesreversecholesteroltransportthroughactivationofampkabctransporterpathway AT huangc canagliflozinfacilitatesreversecholesteroltransportthroughactivationofampkabctransporterpathway AT huangh canagliflozinfacilitatesreversecholesteroltransportthroughactivationofampkabctransporterpathway AT zhangg canagliflozinfacilitatesreversecholesteroltransportthroughactivationofampkabctransporterpathway AT zhouj canagliflozinfacilitatesreversecholesteroltransportthroughactivationofampkabctransporterpathway AT yanj canagliflozinfacilitatesreversecholesteroltransportthroughactivationofampkabctransporterpathway AT xiay canagliflozinfacilitatesreversecholesteroltransportthroughactivationofampkabctransporterpathway AT zhangz canagliflozinfacilitatesreversecholesteroltransportthroughactivationofampkabctransporterpathway AT hej canagliflozinfacilitatesreversecholesteroltransportthroughactivationofampkabctransporterpathway |